Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Optomed

2.79 EUR

-1.06 %

5,644 following
Corporate customer

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

-1.06 %
-23.67 %
-25.99 %
-29.37 %
-25.00 %
-35.57 %
-33.25 %
-54.71 %
-39.08 %

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Read more
Market cap
59.85M EUR
Turnover
160.47K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Buy
Target price
Updated
11.02.2026
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
6.5.
2026

Interim report Q1'26

8.5.
2026

General meeting '26

14.8.
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
Clark Kent raises a very valid point: from a Finnish perspective, the US insurance and reimbursement system is difficult to grasp, and as long as Medicare and private insurance cover an ophthalmologist’s annual check-up, an insured patient has little personal incentive to choose ...
3 hours ago
by Mr. Stock
19
The bearishness Clark_kent is bringing to the thread is quite welcome. There’s at least some slight “copium” noticeable in this thread, and bears are shot down quite aggressively I used to be bullish on Optomed too. Now I’m watching from the sidelines. If you think about, say, a ...
4 hours ago
by Amatööripoimija
11
The customer has certainly spoken, and it shows in the numbers. The monthly billing model isn’t selling—at least not with the kind of volume that would lead to a sudden “ketchup bottle” explosion. The old story that the monthly billing model would lead to significant cash flows didn...
5 hours ago
by Kari
6
And then there’s that $55 reimbursement. Apparently, the most common type of primary care clinic in the USA is a small boutique of 2-5 doctors. Even solo practices make up 15-20%. But a small center like that could serve approx. 5,000 residents. Of them, 12% have diabetes = 600. ...
5 hours ago
6
The US system is so stupid and inefficient. You produce whatever insurance agrees to pay for. $55 is a frustratingly low reimbursement for screening diagnostics. Optomed’s product would be great if it completely replaced a layer in the diagnostic process. But I think the AI algorithm...
15 hours ago
by Clark kent
5
This $55 CPT reimbursement is only one part of this system. Additionally, it includes HEDIS and STAR RATINGS. It has been mentioned that these are more important than CPT for these US healthcare operators. CPT brings immediate cash flow, but HEDIS and STAR bring good bonuses as the...
55 minutes ago
by j.sälli
3
Surely this company would have been acquired by now if others saw it conquering the US market. The company has a camera that others don’t know how to manufacture and the Lumos are flying off the shelves. Heh, of course it would have been bought. As long as others see that there is...
3 hours ago
by Uuno
3
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.